Monte Rosa Therapeutics, Inc. - Common Stock (NQ:GLUE)

18.41 +0.65 (+3.66%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 17, 2026 Add to My Watchlist

Price and Volume

Volume	1,184,533
Open	17.93
Bid (Size)	18.28 (100)
Ask (Size)	19.71 (1,200)
Prev. Close	17.76
Today's Range	17.93 - 19.22
52wk Range	4.120 - 25.77
Shares Outstanding	49,383,711
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 02, 2026

From Monte Rosa Therapeutics, Inc.

Via GlobeNewswire

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

May 20, 2026

From Monte Rosa Therapeutics, Inc.

Via GlobeNewswire

Performance

YTD	+20.2%	+20.2%
1 Month	+2.2%	+2.2%
3 Month	+14.8%	+14.8%
6 Month	-1.3%	-1.3%
1 Year	+282.0%	+282.0%

More News

Monte Rosa Therapeutics Inc (NASDAQ:GLUE) Reports Q1 2026 Results as Clinical Progress Drives Focus on Upcoming Catalysts ↗

May 07, 2026

Via Chartmill

Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

May 07, 2026

From Monte Rosa Therapeutics, Inc.

Via GlobeNewswire

Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 05, 2026

From Monte Rosa Therapeutics, Inc.

Via GlobeNewswire

GLUE Stock Slips Pre-Market After Pricing $300 Million Public Offer At Discount ↗

January 09, 2026

Via Stocktwits

Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise ↗

April 21, 2026

Via The Motley Fool

Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors

April 20, 2026

From Monte Rosa Therapeutics, Inc.

Via GlobeNewswire

Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

March 17, 2026

From Monte Rosa Therapeutics, Inc.

Via GlobeNewswire

Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

March 16, 2026

From Monte Rosa Therapeutics, Inc.

Via GlobeNewswire

Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)

February 24, 2026

From Monte Rosa Therapeutics, Inc.

Via GlobeNewswire

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

February 23, 2026

From Monte Rosa Therapeutics, Inc.

Via GlobeNewswire

3 High-Risk Stocks That Soared in 2025 But Can Still Fly Higher ↗

February 05, 2026

Via MarketBeat

Nasdaq, S&P 500 Futures Pause Ahead Of Jobs Report, Trump Tariff Ruling: Why OPEN, INTC, NVDA, TLRY, CRMD, GLUE Are On Traders' Radar Today ↗

January 09, 2026

Via Stocktwits

Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering

January 08, 2026

From Monte Rosa Therapeutics, Inc.

Via GlobeNewswire

The Great Thaw: Biotech Fundraising Surges as Monte Rosa and Genelux Tap Reopening Markets

January 07, 2026

Via MarketMinute

Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

January 07, 2026

From Monte Rosa Therapeutics, Inc.

Via GlobeNewswire

Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗

January 07, 2026

Via Chartmill

The market is filled with gapping stocks in Wednesday's session. ↗

January 07, 2026

Via Chartmill

Why Did GLUE Stock Surge Over 50% In Premarket Today? ↗

January 07, 2026

Via Stocktwits

Wednesday's pre-market session: top gainers and losers ↗

January 07, 2026

Via Chartmill

Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects

January 07, 2026

From Monte Rosa Therapeutics, Inc.

Via GlobeNewswire

Tuesday's after hours session: top gainers and losers ↗

January 06, 2026

Via Chartmill

Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results

January 06, 2026

From Monte Rosa Therapeutics, Inc.

Via GlobeNewswire

Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations

December 16, 2025

From Monte Rosa Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Monte Rosa Therapeutics, Inc. - Common Stock publicly traded?

Yes, Monte Rosa Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Monte Rosa Therapeutics, Inc. - Common Stock trade on?

Monte Rosa Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Monte Rosa Therapeutics, Inc. - Common Stock?

The ticker symbol for Monte Rosa Therapeutics, Inc. - Common Stock is GLUE on the Nasdaq Stock Market

What is the current price of Monte Rosa Therapeutics, Inc. - Common Stock?

The current price of Monte Rosa Therapeutics, Inc. - Common Stock is 18.41

When was Monte Rosa Therapeutics, Inc. - Common Stock last traded?

The last trade of Monte Rosa Therapeutics, Inc. - Common Stock was at 06/17/26 04:00 PM ET

What is the market capitalization of Monte Rosa Therapeutics, Inc. - Common Stock?

The market capitalization of Monte Rosa Therapeutics, Inc. - Common Stock is 909.15M

How many shares of Monte Rosa Therapeutics, Inc. - Common Stock are outstanding?

Monte Rosa Therapeutics, Inc. - Common Stock has 909M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.